MYC and non-small cell lung carcinoma: A crucial leap toward clinical translation occurred when Dr. Soucek group discovered that the purified Omomyc mini-protein itself possessed unexpected cell-penetrating capabilities, suggesting the feasibility of pharmacological MYC inhibition in vitro an in vivo in different models of NSCLC.414 This pharmacological tool was subsequently developed by Peptomyc S.L. in a first lead product, OMO-103, which entered First-in-Human (FIH) trials in 2021 for patients with advanced solid tumors (NCT04808362).